Evolva Holding company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

evolva.com

Founded Year

2004

Stage

PIPE - III | IPO

Total Raised

$54.41M

Market Cap

0.10B

About Evolva Holding

Evolva Holding develops and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, United States, Denmark, and internationally.

Evolva Holding Headquarters Location

Duggingerstrasse 23

Reinach, CH-4153,

Switzerland

+41 61 485 2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Evolva Holding

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Evolva Holding is included in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

305 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Evolva Holding Patents

Evolva Holding has filed 8 patents.

The 3 most popular patent topics include:

  • Cosmetics chemicals
  • Excipients
  • Food additives
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/27/2016

10/27/2020

Sugar substitutes, Ion channels, Molecular biology, Medicinal plants, Herbs

Grant

Application Date

5/27/2016

Grant Date

10/27/2020

Title

Related Topics

Sugar substitutes, Ion channels, Molecular biology, Medicinal plants, Herbs

Status

Grant

Latest Evolva Holding News

Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan

Jul 26, 2022

Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan Evolva Holding SA / Key word(s): Forecast/Half Year Results 26-Jul-2022 / 07:01 CET/CEST The issuer is solely responsible for the content of this announcement. 53 LR Evolva reports revenues of CHF 8.1 million in the first half of 2022, 28% above the high basis from the prior year period and already 54% of the full-year target Positive double-digit gross contribution margin of slightly above 10% in 1H 2022 Company is well on track to reach its full-year guidance of CHF 15 million revenues and a double-digit gross contribution margin New mid-term plan aims for annual revenue growth of 40-60 % in the coming years, achieving over CHF 20 million revenues in 2023, over CHF 30 million in 2024 and CHF 45-50 million in 2025 Detailed business review leads to cost improvements of CHF 2.3 million and a possible impairment of CHF 15-20 million Constructive discussions with several potential strategic partners ongoing Details on mid-term plan and financial results will be presented on 25 August 2022 Reinach, 26 July 2022 – Evolva (SIX:EVE), a pioneer in the field of natural molecules and industrial biotech, today reports key financial figures of the first half of 2022 as well as targets of its mid-term plan. Evolva achieved a strong sales performance with revenues of CHF 8.1 million in the first semester 2022 despite a slow start into the year. This corresponds to an increase of 28% against a high basis from the prior year period. Sequentially, i.e. compared to the second semester of 2021, the increase was +132%. With 54% of the targeted full-year revenues for 2022 already booked in the first half, Evolva is well on track to reach its 2022 revenue guidance of CHF 15 million. The gross contribution margin in the first half of slightly above 10% is also in line with guidance to achieve a positive double-digit gross contribution margin in 2022. Evolva CEO Christian Wichert, who has joined the company in February this year and undertook a rigorous strategic and operational review of Evolva, comments: “We look back on intensive months of hard work, but also on very satisfactory first results of harvesting initial low hanging fruits and defining a path for future development and growth. My entire team has done a fantastic job in working together to accelerate the commercialization of our product portfolio. As such, we were able to attain a record half-yearly revenue level of CHF 8.1 million during the first six months of 2022, with strong growth especially from Vanillin.” On occasion of yesterday’s meeting, the Evolva Board of Directors approved the new mid-term plan and financial targets as prepared by the leadership team and presented by management. The new mid-term targets aim for annual revenue growth of 40-60 % in the coming years. Specifically, the goal is to generate over CHF 20 million in revenue in 2023. For 2024, Evolva aims to surpass the CHF 30 million mark and targets to reach a revenue level of CHF 45-50 million in 2025. On profitability, the company expects the gross contribution margin to continue to increase significantly, leading to cash and EBITDA break-even in 2025. In addition to focusing on boosting commercial performance, customer proximity, upscaling operations and process development, CEO Christian Wichert and his team are also committed to operational excellence and cost discipline going forward. A review of all spendings with the intention to redirect resources to the focus areas with substantial performance impact resulted in the identification of cost improvements of CHF 2.3 million on an annual basis against the original plan. These cost improvements relate mainly to administrative and overhead costs (e.g. office rents) and will not limit Evolva’s ability to succeed in the market. Analyses are also being conducted on the balance sheet. The company currently expects a non-cash relevant impairment of CHF 15-20 million, with the detailed assessment to be presented together with the half-year results. As previously announced, Evolva is exploring potential strategic partnerships to further strengthen its business model with complementary capabilities and synergies on both operational and commercial levels. Fruitful discussions with several potential strategic partner have been initiated and are currently ongoing. This underscores Evolva’s strong position in nature-based products in the sweet spot of health, wellness and sustainability as well as the attractiveness of the respective market. Christian Wichert adds: “I am excited about our immediate and mid-term prospects. Together with the highly motivated leadership team, we have set ourselves ambitious targets. By focusing on the priority areas commercial excellence, profitability improvement, entrepreneurial culture and team spirit, I am convinced that we can further boost our commercial performance and leverage the positive momentum to bring Evolva to the next level of development.” Evolva will provide a detailed update on the company’s strategy and mid-term targets on occasion of the half-year results on 25 August 2022. Important dates Contact

Evolva Holding Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Evolva Holding Rank

  • When was Evolva Holding founded?

    Evolva Holding was founded in 2004.

  • Where is Evolva Holding's headquarters?

    Evolva Holding's headquarters is located at Duggingerstrasse 23, Reinach.

  • What is Evolva Holding's latest funding round?

    Evolva Holding's latest funding round is PIPE - III.

  • How much did Evolva Holding raise?

    Evolva Holding raised a total of $54.41M.

  • Who are the investors of Evolva Holding?

    Investors of Evolva Holding include Veraison Capital, Nice & Green, Arpida, Aravis Ventures, Wellington Partners and 13 more.

  • Who are Evolva Holding's competitors?

    Competitors of Evolva Holding include Biosyntia, Concert Pharmaceuticals, Catabasis Pharmaceuticals, Viamet Pharmaceuticals, Novira Therapeutics and 13 more.

You May Also Like

P
PhysioGenix

PhysioGenix offers pharmacogenetics and physiological genetics products and services

T
Tequesta Marine Biosciences

Tequesta Marine Biosciences is a specialty pharmaceutical firm that develops small molecule therepeutic drugs for inflammatory conditions.

M
Metastatix

Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.

T
Tolera Therapeutics

Tolera Therapeutics is developing targeted therapies for immune suppression and immune tolerance, designed for use in organ transplant surgeries and other medical settings requiring safer, more targeted immune modulation. The goal is to provide improved induction therapy with a better safety profile than current treatment options. The company's technology, which stems from organ transplant research done at the Cleveland Clinic, has been undergoing clinical research and has been tested in humans. The regulatory pathway is expected to bring a product to market in 2012.

O
Oxagen

Oxagen is a biopharmaceutical company that develops small molecule drugs for inflammatory and respiratory diseases.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.